[
  {
    "title": "Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026",
    "link": "https://www.globenewswire.com/news-release/2026/02/21/3242210/0/en/Abivax-Presents-First-Evidence-of-Anti-Fibrotic-Activity-for-Obefazimod-Alongside-New-Clinical-Efficacy-and-Safety-Analyses-in-Inflammatory-Bowel-Disease-at-ECCO-2026.html",
    "description": "<p align=\"center\"><b>Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026</b></p>",
    "pubDate": "Sat, 21 Feb 2026 11:00 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Biofire",
      "Beacon AI",
      "Grain Weevil",
      "Skyryse"
    ],
    "categories": [
      "milestone"
    ]
  },
  {
    "title": "Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million",
    "link": "https://www.globenewswire.com/news-release/2026/02/21/3242195/0/en/Rakovina-Therapeutics-Announces-Upsized-Financing-Up-to-2-0-Million.html",
    "description": "<p align=\"center\"><em>Proposed $1.0 Million Convertible Debenture and Warrant Financing and\u00a0</em><br><em>Concurrent Common Share Private Placement Up to $1.0 Million </em><br><em>Intended to Support Near-Term Operations</em></p>",
    "pubDate": "Sat, 21 Feb 2026 00:50 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Fortera",
      "Asimov",
      "Profluent"
    ],
    "categories": [
      "funding",
      "product"
    ]
  },
  {
    "title": "K2 Capital Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing on February 25, 2026  \u00a0",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242185/0/en/K2-Capital-Acquisition-Corp-Announces-the-Separate-Trading-of-its-Class-A-Ordinary-Shares-and-Rights-Commencing-on-February-25-2026.html",
    "description": "<p align=\"justify\">NEW YORK, Feb.  20, 2026  (GLOBE NEWSWIRE) -- K2 Capital Acquisition Corp. (the \"Company\") today announced that, commencing on February 25, 2026, holders of the 13,800,000 units (the \u201cUnits\u201d) sold in the Company\u2019s initial public offering (the \u201cOffering\u201d), including Units sold upon full exercise of the underwriters\u2019 over-allotment option, may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on",
    "pubDate": "Fri, 20 Feb 2026 23:00 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Flexport"
    ],
    "categories": [
      "product",
      "ipo"
    ]
  },
  {
    "title": "Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242180/0/en/Psyence-BioMed-Announces-Exercise-of-Put-Option-by-PsyLabs-and-Strategic-Equity-Investment.html",
    "description": "<p align=\"justify\">NEW YORK, Feb.  20, 2026  (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (\u201c<strong>Psyence BioMed</strong>\u201d or the \u201c<strong>Company</strong>\u201d), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (\"<strong>PsyLabs</strong>\") has exercised its rights under a previously disclosed pu",
    "pubDate": "Fri, 20 Feb 2026 22:20 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Zipline",
      "Kinova Robotics"
    ],
    "categories": [
      "funding",
      "product"
    ]
  },
  {
    "title": "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242177/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html",
    "description": "<p>SAN CARLOS, Calif., Feb.  20, 2026  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (\"Iovance\" or the \u201cCompany\u201d), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (\u201cTIL\u201d) therapies for patients with cancer, today announced that on February 19, 2026 (the \u201cDate of Grant\u201d), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance\u2019s common stock to two new, n",
    "pubDate": "Fri, 20 Feb 2026 22:15 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Focused Energy",
      "Fortera",
      "Asimov",
      "Profluent"
    ],
    "categories": []
  },
  {
    "title": "Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares ",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242170/8624/en/Trinity-Biotech-Receives-Non-Compliance-Notice-Regarding-Nasdaq-Global-Select-Requirement-for-Minimum-Market-Value-of-Publicly-Held-Shares.html",
    "description": "<p align=\"justify\">DUBLIN, Feb.  20, 2026  (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (\u201cMVPHS\u201d) of $15,000,000,",
    "pubDate": "Fri, 20 Feb 2026 22:00 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Mammoth Biosciences",
      "Focused Energy",
      "Tempus AI",
      "Oxford Nanopore Technologies",
      "Neko Health"
    ],
    "categories": [
      "ipo"
    ]
  }
]